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Background: High-sensitivity cardiac troponin I (hs-cTnI) assays have been developed that quantify lower cTnI
concentrations with better precision versus earlier generation assays. hs-cTnI assays allow improved clinical
utility for diagnosis and risk stratiﬁcation in patients presenting to the emergency department with suspected
acute myocardial infarction. We describe the High-Sensitivity Cardiac Troponin I Assays in the United States
(HIGH-US) study design used to conduct studies for characterizing the analytical and clinical performance of hscTnI assays, as required by the US Food and Drug Administration for a 510(k) clearance application. This study
was non-interventional and therefore it was not registered at clinicaltrials.gov.
Methods: We conducted analytic studies utilizing Clinical and Laboratory Standards Institute guidance that included limit of blank, limit of detection, limit of quantitation, linearity, within-run and between run imprecision
and reproducibility as well as potential interferences and high dose hook eﬀect. A sample set collected from
healthy females and males was used to determine the overall and sex-speciﬁc cTnI 99th percentile upper reference limits (URL). The total coeﬃcient of variation at the female 99th percentile URL and a universally
available American Association for Clinical Chemistry sample set (AACC Universal Sample Bank) from healthy
females and males was used to examine high-sensitivity (hs) performance of the cTnI assays. Clinical diagnosis of
enrolled subjects was adjudicated by expert cardiologists and emergency medicine physicians. Assessment of
temporal diagnostic accuracy including sensitivity, speciﬁcity, positive predictive value, and negative predictive
value were determined at presentation and collection times thereafter. The prognostic performance at one-year
after presentation to the emergency department was also performed. This design is appropriate to describe
analytical characterization and clinical performance, and allows for acute myocardial infarction diagnosis and
risk assessment.

1. Introduction
Cardiovascular disease is the leading cause of mortality of both men
and women in the United States (US) and worldwide [1]. Biomarkers
are the keystone for making the diagnosis of acute myocardial

infarction (AMI), and cardiac troponin (cTn) is the preferred biomarker
for aiding in the AMI diagnosis in patients presenting to the emergency
department (ED) with signs and symptoms of AMI [2]. Since their entry
into US practice in 1995 [3–6], cTn assays have evolved in analytical
sensitivity, which has translated clinically into earlier diagnosis and

Abbreviations: IM, immunoassay; hs-cTnI, High-Sensitivity Troponin I; PPV, positive predictive value; NPV, negative predictive value; ACS, acute coronary syndrome; AMI, acute myocardial infarction; MDP, Medical Decision Pools; CLSI, Clinical and Laboratory Standards Institute; Li-Hep, lithium heparin; cTn, cardiac
troponin; cTnI, cardiac troponin I; hs-cTn, high-sensitivity cardiac troponin; LoB, Limit of Blank; LoD, Limit of Detection; LoQ, Limit of Quantitation; URL, upper
reference limit
∗
Corresponding author. University of Maryland Medical Center, Laboratories of Pathology, 22 South Greene Street, Baltimore, MD, 21201, USA.
E-mail address: rchristenson@umm.edu (R.H. Christenson).
https://doi.org/10.1016/j.conctc.2019.100337
Received 19 December 2018; Received in revised form 22 January 2019; Accepted 13 February 2019
Available online 15 February 2019
2451-8654/ © 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).

Contemporary Clinical Trials Communications 14 (2019) 100337

R.H. Christenson, et al.

earlier rule-out of AMI. The most analytical sensitive assays are termed
‘high-sensitivity cardiac troponin’ (hs-cTn), and have been deﬁned per
recommendations of the Academy of the American Association for
Clinical Chemistry (AACC) and the International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC)'s Committee for Clinical
Application of Cardiac Bio-markers (C-CACB) [2,7–11]. These recommendations address 1) total imprecision at the sex speciﬁc 99th
percentile upper reference limit (URL) of healthy men and women must
be less than or equal to a total coeﬃcient of variation (CV) of 10%; and
2) at least 50% of samples from cohorts of healthy men and healthy
women must each have cTn values equal to or exceeding the assay's
limit of detection (LoD) [7]. Although the deﬁnition of hs-cTn assays is
analytical, the beneﬁts of these hs-cTn assays are intended to be clinical, and include earlier time to AMI diagnosis after acute cardiac events
[7].
Appropriate study design and conduct of studies intended for
characterizing hs-cTn assays are essential for assuring that any device is
safe and eﬀective for use in patient care. Our purpose is to present an
approach for designing and conducting US Food and Drug
Administration (FDA) 510(k) investigations that characterize hs-cTnI
assays, both analytically and clinically. This methodology was used to
determine the nature of multiple Siemens Healthcare Diagnostics Inc.
(“Siemens Healthineers”) hs-cTnI assay systems intended as an aid for
diagnosis and risk assessment of patients presenting to EDs with signs
and symptoms suggestive of AMI.

Table 1
Blood sample collection timetable.
Group

Targeted Blood Collection Times

1

T0: baseline (within ± 90 min of the ﬁrst local standard of care blood
draw for troponin)
T1: 45–75 min after T0
T3: 2–3 h after T0
T6-9: 6–9 h after T0
T12-24: 12–24 h after T0

2
3
4
5

presenting to the ED with symptoms suspicious for AMI as determined
by the treating ED physician and able to be enrolled within 1.5 h of
their ﬁrst clinical blood draw. Possible symptoms of ischemia include
one or more of the following: chest, upper extremity, mandibular, or
epigastric discomfort during exertion or at rest, or dyspnea or fatigue
[2,10]. The study had no enrollment exclusion criteria, except that
patients had to be willing to participate and provide informed consent
in accordance with Institutional Review Board requirements. Patients
were enrolled over the time period from April 2015 to April 2016.
Paired Li-Hep and serum baseline samples were collected as soon as
possible after presentation and obtaining informed consent (T0), and at
the following four additional time points displayed in Table 1 whenever
possible. Samples collected outside of these time windows were retained and tested. All samples were centrifuged within four hours of
collection, held at 4 °C until separation into six to seven aliquots to
create six sets of ED samples that were then frozen and stored locally at
−20 °C or colder within six hours of collection. Samples were all
shipped to a Core Laboratory repository on dry ice where they remained
frozen during organization and were thereafter maintained at −70 °C
or colder. Hospitalized subjects known to have elevated cTn levels were
enrolled in a stability study and matched Li-Hep and serum samples
were collected from each subject. Samples were centrifuged within two
hours of collection. Fresh aliquots were immediately tested by the
ADVIA Centaur TNIH assay. The remainder of the plasma and serum
was aliquoted into cryovials and frozen at −70 °C up to 690 days. At
regular time intervals, aliquots were thawed and cTnI measured using
the TNIH assay. Data were plotted with % bias on the y-axis and
number of days on the x-axis. A linear regression was performed. The
sample stability duration is estimated as one day before the one-sided
95% conﬁdence interval of the regression line intersects with the acceptance criterion of ± 10% bias. (Data not included here; however,
stability data will be included in a relevant publication utilizing the
HIGH- US samples.)

2. Materials and methods
2.1. Clinical performance studies
2.1.1. Ethics and governance
Documented approval was obtained from the local Institutional
Review Board from all participating centers before the study initiation
at a clinical site, according to Good Clinical Practice and local laws and
regulations. Written informed consent was obtained from all participants as part of enrollment.
2.1.2. 99th percentile upper reference limits (URLs)
Studies were conducted in a healthy population recruited in accordance with Clinical and Laboratory Standards Institute (CLSI)
document EP28-A3c [12] using both lithium heparin plasma (Li-Hep)
and serum samples. Twelve sites across the US enrolled subjects 22
years or older, who completed a comprehensive medical history questionnaire and self-reported that they were in generally good health with
no symptoms of heart disease. Subjects with the following ﬁndings were
excluded from enrollment in the study: history of vascular or cardiovascular disease, hypertension, diabetes mellitus, chronic renal disease,
rheumatoid arthritis, muscle/skeletal disease or injury currently under
the care of a physician, cancer, history of heavy alcohol intake (deﬁned
as consuming on average more than two drinks per day or more than 14
drinks per week for men, and on average more than one drink per day
or more than seven drinks per week for women; one drink is approximately 14 gm of pure alcohol), morbid obesity deﬁned as body mass
index (BMI) above 40, and pregnancy. Subjects were also excluded from
enrollment if taking cardio-active drugs with the exceptions of aspirin
and statins taken in prophylaxis or for dyslipidemia without a conﬁrmed diagnosis of atherosclerosis. Enrollment was stratiﬁed per age
group and sex in order to include a population representative of the US.
For analysis of the 99th percentile URL from healthy subject study,
the SAS System for Windows (ver. 9.3) was used to compute the 99th
percentile URL non-parametrically in accordance with CLSI guideline
EP28-A3c [12], with PROC Univariate using the type 4 deﬁnition. The
90% conﬁdence interval was also computed.

2.1.4. Sample testing
Characterization of analytical parameters was determined for the
Atellica® IM TnIH, ADVIA Centaur® TNIH, Dimension Vista® 1500 TNIH,
and Dimension EXL® 200 TNIH™ Systems in respective clinical trials. By
design, the characterization testing for each system was examined at
three sites, each of which performed approximately one third of the
required testing. Samples were shipped on dry ice from the Core
Laboratory in batches to the three qualiﬁed clinical testing sites. The
study was designed to collect samples within the protocol targeted time
windows (Table 1); however samples collected outside of these windows were eligible for analysis.
2.1.5. Subject clinical classiﬁcation
Patients were classiﬁed for AMI status by adjudication, based on the
Third Universal Deﬁnition of Myocardial Infarction consensus guideline
endorsed by the European Society of Cardiology (ESC), the American
College of Cardiology Foundation (ACCF), the American Heart
Association (AHA), and the World Heart Federation (WHF) [10]. Subject demographics, height, weight, time of onset of last symptoms to
blood draw, time for ﬁrst blood draw from ED presentation, ED admission information, cardiac therapies, cardiac risk factors, medical

2.1.3. Clinical performance in the emergency department
Twenty-nine sites across the US enrolled subjects, ≥22 years of age,
2
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sandwich immunoassays sharing the same assay design, antibodies
(Abs) and direct chemiluminometric technology (Fig. 1 Panel A). Capture epitopes are amino acids 41–50 and 171–190; and the detection
epitopes are amino acids 29–34 [13]. Solid Phase Reagent is made of
magnetic latex particles conjugated with streptavidin and two bound
biotinylated capture monoclonal Abs (one sheep and one mouse) each
recognizing a unique cTnI epitope. (The two Abs are pre-bound to the
solid phase reagent via streptavidin which eliminates biotin interference.) The solid phase-cTnI complex is detected through binding to
Lite Reagent, which consists of recombinant anti-human cTnI sheep Fab
and acridinium ester tag for chemiluminescent signaling [14], each
bound to bovine serum albumin. A direct relationship exists between
the amount of cTnI present in the sample and the amount of chemiluminescent generated relative light units detected by the system [15,16].
The Dimension EXL and Dimension Vista TNIH assays share the
same assay design and Abs (Fig. 1 Panel B). The capture epitopes recognized by Abs are amino acids 29–34; the detection epitopes recognized by Abs are amino acids 41–50 and 171–190 [13]. As indicated
in Fig. 1 Panel B, the assays employ Luminescent Oxygen Channeling
Immunoassay (LOCI) technology that utilizes two sheep monoclonal
Abs, one is an intact antibody that coats chemibeads (capture) and the
other is an F(ab’)2 fragment (detection), plus one mouse monoclonal
Fab fragment (detection). cTnI in the patient sample is ‘sandwiched’
between the chemibead-sheep monoclonal Ab conjugate and the biotinylated sheep F(ab’)2 and mouse Fab fragments that then bind to
streptavidin-coated sensibeads. Sensibeads bind tightly to available Abbiotin sites on the complex, bringing the acridinium ester chemiluminescent dye particle in close proximity. Exposure of sensibeads to light
at 680 nm leads to their release of short-lived singlet oxygen (1O2)
molecules that react with the acridinium ester in the capture-Ab bead. A

history, concurrent therapies, ED discharge summary or transfer note,
hospital discharge summary, and treating ED physician initial suspicion
of ACS prior to knowing the ﬁrst cTn measurement result and local
standard of care cTn results were provided to the adjudicators. The 29
enrolling sites used any FDA cleared cTn assays (see Supplemental
Table 1 for listing) to perform the local standard of care cTnI measurements used for the adjudication. A total of 25 adjudicators were
involved. To avoid possible adjudicator panel bias, data for each subject
was reviewed by a unique combination of ﬁve adjudicators. Approximately half the panels included two cardiologists and three emergency
physicians, and half included three cardiologists and two emergency
physicians. The majority rule was applied to determine the ﬁnal AMI
classiﬁcation. Adjudicators were blinded to cTnI results from the new
Siemens Healthineers assays being examined and to the patient diagnosis established by the treating hospital. The adjudicators had access
to both the manufacturers’ package insert cutoﬀs and to the locally
established cTn cutoﬀs (where applicable) for the diagnosis of AMI.
Each adjudicator independently used their expert opinion to assess if
the requirements of an AMI adjudicated diagnosis were met, including
the presence of a clinically signiﬁcant rise and/or a fall of cTn levels, as
determined by the experienced adjudicators. For this study no relative
or absolute threshold was pre-speciﬁed for a signiﬁcant rise and/or fall
of cTn levels.
2.2. Analytical performance studies
Characterization of the analytical parameters was determined for
the Atellica IM TnIH, ADVIA Centaur TnIH, Dimension Vista 1500
TnIH, and Dimension EXL 200 TnIH Systems in respective clinical trials.
The Atellica IM TnIH and ADVIA Centaur TNIH assays are three-site

Fig. 1. Panel A. Siemens Healthineers' hs-cTnI assay architecture for the Atellica IM TnIH Assay and the ADVIA
Centaur XP/XPT TNIH assays. Patient sample containing cTn
complexes and fragments is mixed with the solid phase
magnetic latex beads coated with sheep and mouse monoclonal Abs for capture of cTnI. Lite reagent is also added and
contains anti-human recombinant sheep Fab fragment linked
to bovine serum albumin (BSA) labeled with acridinium ester
(chemiluminescent signal producing substance). The complex is washed and addition of acid/base reagent results in a
chemiluminescent signal read by the detection system. The
time to ﬁrst result with the Atellica IM TnIH Assay TTFR is
9.8 min; the analytical time for the ADVIA Centaur XP/XPT
TNIH assay is 18 min.
Panel B. Components of Luminescent Oxygen Channeling
Immunoassay (LOCI) technology used for hs-cTnI measurement on the Dimension Vista and EXL Systems. Dye containing chemibeads coated with sheep monoclonal anti-cTnI
Abs (capture) and two soluble, biotin labeled monoclonal Ab
fragments (one sheep and one mouse) are added to samples
containing cTnI to form [Capture-Ab:cTnI:Ab-Biotin] complexes. A streptavidin-coated particle reagent capable of
generating singlet oxygen (Sensibead) is added to the mixture. Sensibeads bind avidly to available Ab-biotin sites on
the complex, thereby tethering the acridinium ester chemiluminescent dye particle in close proximity. Upon exposure
to light at 680 nm, the Sensibeads release short-lived singlet
oxygen (1O2) molecules that react with the chemiluminescent
dye in the capture-Ab bead, causing emission of light at
612 nm, which is read by the detection system. The time to
ﬁrst result on both systems is 10 min.

3
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Method comparison studies were conducted in accordance with
CLSI document EP09-A3 for the various assays [21]. A minimum of 950
samples was used across the assay range. In this way, harmonization
between the systems could be determined with one cTnI reagent lot.
Analytic speciﬁcity was tested using human samples containing
cTnI concentrations near the overall 99th percentile URL of healthy
individuals for each platform. Substances including cardiac troponin T,
skeletal troponin I, tropomyosin, actin, troponin C, myosin light chain,
myoglobin or CK-MB were added, each at a concentrations of
1,000,000 ng/L. Results from the tested hs-cTnI assay system for the
spiked samples were compared with those of unspiked control samples.
Cross-reactivity, in percent, was determined in accordance with CLSI
Document EP07-A2 [22] and was calculated as:

chemiluminescent signal is triggered and measured at 612 nm, and is a
direct function of the cTnI concentration in the sample [17,18].
Detection Capability of the systems was performed in accordance
with CLSI document EP17-A2 [19].
Limit of blank (LoB), deﬁned as the 95th percentile value of assay
blank samples (e.g., Li-Hep or serum samples in which cTn epitopes
were masked) was performed using a nonparametric statistical approach. The details for each system varied; however, each study included a minimum of two reagent lots, measured on three nonconsecutive days for each instrument system, and included at least four
blank samples. LoB analysis was performed on both Li-Hep plasma and
serum sample matrices. A representative study, performed using an
Atellica IM Analyzer, employed four Li-Hep plasma blanks and four
serum sample blanks, with each of three unique hs-cTnI reagent lots. A
total of 1440 measurements were obtained with 480 measurements per
reagent lot or 240 measurements for each reagent lot/sample matrix
combination. The claimed LoB for the Siemens Healthineers hs-cTnI
assay represents the highest LoB observed for all combinations of reagent lots/sample.
Limit of detection (LoD), deﬁned as the lowest analyte concentration detected above the LoB with a probability of 95%, was determined
based on LoB and standard deviation (SD) of low concentration samples. Testing included a minimum of two reagent lots, measured on
three days, on two systems for each type of instrument system. LoD
analysis was performed on both Li-Hep and serum sample matrices. For
example, the Atellica IM Analyzer study included 13 samples (six low
cTnI Li-Hep plasma pools and seven low cTnI serum pools) in a 20 day,
two run per day, three reagent lots, on a minimum of two analyzers,
collecting a total of 1040 measurements. The LoD represents the highest
calculated LoD across all combinations of instruments, sample matrices
and reagent lots.
Limit of quantitation (LoQ), or functional sensitivity, was estimated
in accordance with CLSI document EP17-A2 and CLSI document EP05A3 [19,20]. The LoQ represents the highest observed concentration at
20% CV and the highest concentration determined from the individual
reagent lot and instrument combination. As an example, the Atellica IM
Analyzer study included three reagent lots tested, and the sample types
included six low cTnI Li-Hep plasma pools and seven low cTnI serum
pools. For each reagent lot and instrument combination, the within-lab
precision over 20 days for each sample, expressed as percent %CV, was
plotted against the mean concentration of each sample. Data were ﬁtted
using a power function to yield a precision proﬁle.
Analytical measurement range (AMR), or linearity was determined
by a series of Li-Hep and serum samples containing cTnI measured in
triplicate spanning from the LoQ to the upper measurable limit without
dilution. Patient samples exceeding the upper range of reportable results were auto-diluted. Onboard auto-dilutions were performed for all
systems using Siemens Healthineers speciﬁed diluent.
Precision studies were performed in accordance with CLSI document EP05-A3 to assess repeatability (within-run) and total (within-lab)
imprecision [20]. The studies used multiple reagent lots, one calibrator
lot per reagent lot, and multiple systems per study. The systems were
calibrated every 14 days, and the testing included 20 test days, two runs
per test day with a minimum of two hours in between, and two replicate
measurements per sample. Samples included control serum pools;
contrived high and low spiked Li-Hep plasma and serum samples. Fresh
frozen aliquots were thawed daily.
Reproducibility, i.e., between site imprecision, was determined at
multiple cTnI concentrations at three sites, over ﬁve days, with two
runs per day and three replicates per run using one lot of reagent and
one lot of calibrator in accordance with CLSI document EP05-A3 [20].
These data were utilized to assess reproducibility, repeatability and
within-laboratory precision for the three sites. Reproducibility was estimated by incorporating laboratory-to-laboratory, instrument-to-instrument and within-laboratory imprecision in accordance with CLSI
document EPO5-A3 [20].

(hs − cTnI concentration of spiked sample − hs
% cross − reactivity

=

− cTnI concentration of unspiked sample )
Concentration of substance spiked into sample
× 100%

Interference testing was performed in Li-Hep plasma and serum
samples having cTnI concentrations near the 99th percentile URLs of
20–60 ng/L and at a more elevated value of 1000–2000 ng/L in accordance with CLSI document EP07-A2 [22]. Compounds for interference testing included hemoglobin, triglycerides, conjugated bilirubin, unconjugated bilirubin, biotin, cholesterol, and over 50
cardiovascular-associated drugs. A cTnI value ≤ 10% of the initial
target cTnI value was considered as no interference.
High Dose Hook Eﬀect was examined with Li-Hep samples with
cTnI values up to 500,000 ng/L, i.e., 20-fold higher than the assay's
AMR of 25,000 ng/L. Reporting of a value other than ‘ > 25,000 ng/L’
was considered positive for the high dose hook eﬀect.
High-Sensitivity Performance Assessment. This was determined as
recommended by the AACC Academy and IFCC Committee for Clinical
Application of Cardiac Bio-markers (C-CACB) [7]. Total imprecision at
lowest sex-speciﬁc 99th percentile URL was determined according to
CLSI document EP12-A2 [23]. Assays were used to measure samples
from healthy cohorts of ≥300 men and ≥300 women to determine
if ≥ 50% of each sex had cTnI values equal to or exceeding the assay's
deﬁned LoD. For this determination, a commonly available cohort, the
AACC Universal Sample Bank (USB), was utilized [24]. The characteristics of this repository have been described previously [24], but brieﬂy
all samples were collected from self-selected volunteers that participated in The AACC USB activity as part of the 2015 AACC Annual
Meeting and Exposition in Atlanta, GA (84% of samples) or were individuals from the Baltimore, MD community (16% of samples), who
volunteered to participate within the same time frame at the University
of Maryland School of Medicine (Baltimore, MD). The protocol and
conduct of the AACC USB was approved by Emory University's Institutional Review Board. Specimens were processed and frozen on dry
ice within 60 min of collection, and then stored at −70 °C in the Repository at the Center for Disease Control and Prevention in Atlanta,
GA. To examine for possible underlying health conditions, aliquots of
samples from all subjects were tested for the surrogate biomarkers
Amino-terminal proB-type natriuretic peptide (NT-proBNP); hemoglobin A1c; and creatinine, which was used with each subject's age,
sex and race to estimate glomerular ﬁltration rate with the equation
from the Chronic Kidney Disease (CKD) Epidemiology Collaboration as
described earlier [25].

2.3. Statistical methods: clinical performance analyses
2.3.1. Hypotheses
The study tested the following hypotheses. H0: The assay has sensitivity for AMI greater than or equal to 90%; H1: The assay has less
than 90% sensitivity.
4
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another assay. This report describes the design and rationale for the
analytical and clinical performance validation of hs-cTnI assays in ED
patients presenting with signs and symptoms of AMI across the US. Here
we describe the study design and conduct for characterizing hs-sTnI and
for determining the optimal clinical cutoﬀ points for safe and eﬀective
rule-out and rule-in of AMI in ED populations, based on FDA 510 (k)
requirements. For rule-out, guideline recommended optimal cTnI cutoﬀ
points are detection capability parameters (e.g., LoD) and low cutoﬀ
values [32], and for rule-in, the guideline recommended optimal cut
point is the 99th percentile URL with a temporal rise and/or fall in cTn
levels. Superior precision is imperative for both rule-out strategies
based on the LoD or low cutoﬀ values, for determining signiﬁcant
changing patterns, and for rule-in strategies based on the 99th percentile. Additionally, this study collected samples and data to allow
evaluation of the prognostic utility of hs-cTnI assays up to one year
after the index presentation.
hs-cTnI assays and accelerated protocols (0/1-h, 0/2-h, and 0/3-h),
often termed Accelerated Diagnostic Protocols (ADPs), have been in use
for several years outside the US, (e.g., Europe, Australia, and New
Zealand) [32,33]. As hs-cTn assays become available in the US, some of
these accelerated protocols may be safely adopted, due to the improved
sensitivity and precision of the hs-cTn assays [34].

2.3.2. Sample size
This protocol describes the enrollment of up to 3000 ED subjects to
support the validation of multiple Siemens Heatlhineers TnI assays;
however, we tested approximately 2000 of these subjects on each individual assay. For the assessment of diagnostic accuracy and prognostic performance in subjects with AMI, we included a minimum of
approximately 2000 adults who presented for emergency care with
signs and symptoms of ACS. We anticipated approximately 8%–12%
would be diagnosed with AMI, representing 160 to 240 subjects. Given
a sensitivity of 90% and an alpha of 0.05 (95% conﬁdence), a sample of
179 subjects would have 80% power to detect a diﬀerence of 6% or
greater between the hypotheses.
2.3.3. Diagnostic accuracy
This was deﬁned as the medical concordance between the 99th
percentile URL and the presence or absence of AMI diagnosis at each of
the time points. In addition to the pooled assessment for all subjects,
separate assessments were conducted for each sex-speciﬁc subgroup
using sex-speciﬁc speciﬁc 99th percentile URLs previously established
using the population of apparently healthy subjects. Four measures of
diagnostic performance were calculated: sensitivity, speciﬁcity, positive
predictive value, and negative predictive value. Sensitivity was deﬁned
as the proportion of subjects with an assay result above the cutoﬀ
among all subjects diagnosed with AMI. Speciﬁcity was deﬁned as the
proportion of subjects with an assay result equal to or below the cutoﬀ
among all subjects not diagnosed with AMI. Positive predictive value
was deﬁned as the proportion of subjects diagnosed with AMI among all
subjects with assay results above the cutoﬀ. Negative predictive value
was deﬁned as the proportion of subjects not diagnosed with AMI
among all subjects with assay results equal to or below the cutoﬀ. The
95% Wilson score conﬁdence intervals for sensitivity, speciﬁcity, positive predictive value and negative predictive value were estimated
[26].
Prognostic performance was assessed at 30-day, 90-day, 182-day
and 365-day after baseline T0. Endpoints were mortality from all causes
and major cardiac events including cardiovascular death, non-fatal MI,
heart failure admission, stroke, or revascularization after the index
admission. The product-limit method of Kaplan-Meier was used to estimate survivorship, i.e., the proportion of subjects with an initial T0
reading above the cut-oﬀ who reach endpoints within 30, 90, 182 and
365 days, for all subjects and for each sex-matrix subgroup. Cox regression was used to calculate the hazard ratios for each sex-matrix
subgroup. A hazard ratio was deﬁned as the proportion of subjects with
an initial T0 reading above the cutoﬀ who reach endpoints divided by
the proportion of subjects with an initial T0 reading equal to or below
the cutoﬀ who reach endpoints. Adjustment for demographics, traditional cardiovascular risk factors, presence of known cardiovascular
disease, and renal function was also assessed.

3.2. Central role of cardiac troponin for management of coronary heart
disease and other diseases
As with the Third Universal Deﬁnition of MI used for adjudication in
the current study design, the Global Task Force for the Fourth Universal
Deﬁnition of MI deﬁnes myocardial injury (cell necrosis/death) as detection of cTn values above the 99th percentile. A 2018 expert consensus document by the AACC Academy and IFCC Committee for
Clinical Application of Cardiac Bio-markers (C-CACB) has provided an
update to the deﬁnition and analytical performance requirements of
cTn assays [7,9,10,35].
hs-cTnI measurements will be used in diseases other than suspected
AMI including perioperative myocardial injury associated with noncardiac procedures [2], such as heart failure and Takotsubo syndrome
[2], and diﬀerent study designs will need to be developed for those
applications. Also, diseases other than ACS myocardial injury may be
associated with non-ischemic, non-cardiac (systemic) conditions such
as chronic kidney disease. Elevations above the 99th percentile URL
have been observed in most end-stage renal disease patients when using
hs-cTn assays, and documenting a changing temporal pattern for diagnosing AMI is important for the CKD and dialysis populations, just as
it is for patients with normal renal function [36].
3.3. Strength of study design
Several experienced clinical trial experts along with the US FDA
reviewed early protocols and made recommendations to the study design. The clinical experts have participated in several similar trials on
patients presenting to the ED with suspected AMI for other cTn assays,
and have published their ﬁndings in peer-reviewed journals [37–44]. In
addition, these experts have contributed to setting international
guidelines for use of hs-cTn assays [2,7,9,35]. By design, all subjects
presenting to the ED with signs and symptoms of AMI were eligible for
inclusion in this study. Not excluding any patients presenting with
suspected AMI translates into the ﬁndings being more applicable to an
unbiased population, as seen in real-life clinical scenarios. In addition,
clinicians will have more conﬁdence to use these hs-cTnI assays. Other
strengths include that the study was prospective and samples were
collected at multiple sites throughout the US; samples were designed to
be collected from a large population of diverse subjects; cTnI values
were measured in real-world laboratories as well as at Siemens Healthineers (customer simulated environment laboratories). Furthermore,
endpoint adjudication used a large pool of experts with diverse

3. Discussion
3.1. Importance of study design for safety and eﬀectiveness
Each year, approximately 10 million people in the US present to the
ED with signs and symptoms suggestive of AMI; of these, 625,000 patients (∼6.25%) are diagnosed with ACS. Of the 625,000 ACS patients,
70% (437,500) are ultimately diagnosed with non–ST-elevation
(NSTE)-ACS (NSTEMI plus unstable angina) that are often not identiﬁed
by the ECG [27,28]. Accurate and rapid identiﬁcation of AMI patients is
critical to saving lives, and avoiding unnecessary procedures, lengthy
stays and overcrowding in EDs, patient anxiety, and associated
healthcare costs [2,10,29–31]. Analytically, hs-cTnI assays are superior
for detecting very low cTn concentrations with far better precision than
contemporary assays used in the U.S currently.
hs-cTnI assays are not harmonized or standardized; therefore, values from one assay cannot be directly compared with those from
5
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Author contributions

backgrounds. Compared to earlier studies, our intention was to draw
the study's ﬁrst sample (T0) as close as possible to specimen collected
for clinical use.

All authors made substantial contributions to this manuscript. All
authors were involved in drafting the manuscript and critically revising
it for intellectual content and accuracy. All authors have approved the
ﬁnal version of the manuscript for publication.

3.4. Limitations
This study design has several limitations. First, results generated
from this US study may not apply to situations outside of the US.
Furthermore, the use of multiple local cTn assays to determine the
adjudicated diagnosis of AMI may have provided a reference standard
that was less than perfect because some of the standard of care assays
were clearly inferior to the Siemens Healthineers comparator. Second, a
possible limitation was the use of a healthy control population that may
have resulted in 99th percentile URL values that were distinctly lower
than the usual population of patients presenting to the ED with suspected ACS. Although no healthy individuals had evidence of cardiovascular disease, some subjects taking statins were enrolled which may
have lowered cTn values [45]. Using this population likely increased
the sensitivity compared to a population with a baseline rate of coexistent pathology, e.g., patients with diabetes, who smoked, and had a
prior AMI, etc. Third, although there were no enrollment exclusions, we
did not collect samples from all patients presenting to the ED, seven
days a week, 24 h a day, so there may have been a selection bias.
Further, some eligible patients chose not to participate. Fourth, the
investigative teams were unable to obtain samples at all time points
from every patient. Furthermore, the volume available for some samples limited testing of all samples on all platforms at all time points,
which could have aﬀected diagnostic and/or prognostic performance.
Although substantial eﬀorts were made to collect the initial study
sample as close as possible to the ﬁrst clinical specimen, the unavoidable requirement for an appropriate informed consent process necessarily delayed the collection of the ﬁrst study sample (T0) compared
to timing of the earliest clinical sample.
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3.5. Conclusion
This study will be used to deﬁne the analytical and clinical performance of the Atellica TnIH, ADVIA Centaur TNIH, Dimension EXL
TNIH, and Dimension Vista TNIH assays, based on FDA requirements
for patient enrollment. Analytical parameters (LoB, LoD, LoQ) at the
lower end of the assay range, imprecision, linearity, 99th percentile
URL diagnostic cutoﬀ values, and high-sensitivity performance were
determined and used to assess safety and clinical eﬃcacy of the assay
for AMI diagnosis and one-year prognosis. Improving triage of myocardial injury patients will lead to better management of patients,
thereby improving outcomes and decreasing medical costs.

Appendix A. Supplementary data
3.6. Clinical perspectives
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.conctc.2019.100337.

More accurate diagnosis of AMI and myocardial injury conditions
using hs-cTnI assays can lead to more timely and eﬃcient triage, more
accurate therapeutic and management approaches, reduced time in the
ED, reduced healthcare costs, reduced disease complications, and improved clinical outcomes.

References
[1] E.J. Benjamin, S.S. Virani, C.W. Callaway, A.M. Chamberlain, A.R. Chang, S. Cheng,
et al., Heart disease and stroke statistics-2018 update: a report from the American
Heart Association, Circulation 137 (2018) e67–e492 https://doi.org/10.1161/cir.
0000000000000558.
[2] K. Thygesen, J.S. Alpert, A.S. Jaﬀe, B.R. Chaitman, J.J. Bax, D.A. Morrow, et al.,
Fourth universal deﬁnition of myocardial infarction (2018), J. Am. Coll. Cardiol. 72
(2018) 2231 https://doi.org/10.1016/j.jacc.2018.08.1038.
[3] E.M. Antman, M.J. Tanasijevic, B. Thompson, M. Schactman, C.H. McCabe,
C.P. Cannon, et al., Cardiac-speciﬁc troponin I levels to predict the risk of mortality
in patients with acute coronary syndromes, N. Engl. J. Med. 335 (1996) 1342–1349
https://doi.org/10.1056/nejm199610313351802.
[4] J.P. Bertinchant, C. Larue, I. Pernel, B. Ledermann, P. Fabbro-Peray, L. Beck, et al.,
Release kinetics of serum cardiac troponin I in ischemic myocardial injury, Clin.
Biochem. 29 (1996) 587–594.
[5] J. Ravkilde, H. Nissen, M. Horder, K. Thygesen, Independent prognostic value of
serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light

Acknowledgements
Funding
The HIGH-US study was supported/funded by Siemens
Healthineers, 511 Benedict Avenue, Tarrytown, NY 10591, USA. This
research did not receive any speciﬁc grant from funding agencies in the
public, or not-for-proﬁt sectors.
OR, if open access the following would be used
This work is funded/supported by Siemens Healthineers Laboratory
Diagnostics Inc.
6

Contemporary Clinical Trials Communications 14 (2019) 100337

R.H. Christenson, et al.

[6]
[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

chain levels in suspected acute myocardial infarction. Analysis of 28 months of
follow-up in 196 patients, J. Am. Coll. Cardiol. 25 (1995) 574–581 https://doi.org/
10.1016/0735-1097(94)00430-x.
A.H. Wu, P.L. Lane, Metaanalysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases, Clin. Chem. 41 (1995) 1228–1233.
A.H.B. Wu, R.H. Christenson, D.N. Greene, A.S. Jaﬀe, P.A. Kavsak, J. OrdonezLlanos, et al., Clinical laboratory practice recommendations for the use of cardiac
troponin in acute coronary syndrome: Expert opinion from the Academy of the
American Association for Clinical Chemistry and the Task Force on Clinical
Applications of Cardiac Bio-Markers of the International Federation of Clinical
Chemistry and Laboratory Medicine, Clin. Chem. 64 (2018) 645–655 https://doi.
org/10.1373/clinchem.2017.277186.
E.A. Amsterdam, N.K. Wenger, R.G. Brindis, D.E. Casey Jr., T.G. Ganiats,
D.R. Holmes Jr.et al., AHA/ACC guideline for the management of patients with nonST-elevation acute coronary syndromes: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines,
Circulation 130 (2014) e344–426 2014 https://doi.org/10.1161/CIR.
0000000000000134.
F.S. Apple, A.S. Jaﬀe, P. Collinson, M. Mockel, J. Ordonez-Llanos, B. Lindahl, et al.,
IFCC educational materials on selected analytical and clinical applications of high
sensitivity cardiac troponin assays, Clin. Biochem. 48 (2015) 201–203 https://doi.
org/10.1016/j.clinbiochem.2014.08.021.
K. Thygesen, J.S. Alpert, A.S. Jaﬀe, M.L. Simoons, B.R. Chaitman, H.D. White, et al.,
Third universal deﬁnition of myocardial infarction, Circulation 126 (2012)
2020–2035 https://doi.org/10.1161/CIR.0b013e31826e1058.
K. Thygesen, J. Mair, E. Giannitsis, C. Mueller, B. Lindahl, S. Blankenberg, et al.,
How to use high-sensitivity cardiac troponins in acute cardiac care, Eur. Heart J. 33
(2012) 2252–2257 https://doi.org/10.1093/eurheartj/ehs154.
Clinical and Laboratory Standards Institute, Deﬁning, Establishing, and Verifying
Reference Intervals in the Clinical Laboratory; Approved Guideline, third ed.,
Clinical and Laboratory Standards Institute, Wayne, PA, 2010 CLSI Document EP28A3c.
High-Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics
Designated by Manufacturer IFCC Committee on Clinical Applications of Cardiac
Bio-Markers (C-CB) v082318, (2018) http://www.ifcc.org/media/477441/highsensitivity-cardiac-troponin-i-and-t-assay-analytical-characteristics-designated-bymanufacturer-v08232018.pdf , Accessed date: 4 December 2018.
A. Natrajan, D. Wen, A comparison of chemiluminescent acridinium dimethylphenyl ester labels with diﬀerent conjugation sites, Org. Biomol. Chem. 13 (2015)
2622–2633 https://doi.org/10.1039/c4ob02528h.
Siemens Healthcare Diagnostics, ADVIA Centaur® XP, ADVIA Centaur® XPT HighSensitivity Troponin I (TNIH) Assay instructions for use. 11200076_EN, rev. A.
Siemens, Tarrytown (NY), 2017 Mar.
Siemens Healthcare Diagnostics, Atellica® IM High-Sensitivity Troponin I (TnIH)
assay instructions for use, OUS. 11200497_EN Rev. 03 Tarrytown (NY), Siemens,
2018 July.
Siemens Healthcare Diagnostics, Dimension® EXL™ LOCI® High-Sensitivity
Troponin I (TNIH) assay instructions for use. PN 10866031, rev D, Siemens,
Tarrytown (NY), 2017 Oct.
Siemens Healthcare Diagnostics, Dimension Vista® High Sensitivity Troponin I
(TNIH) assay instructions for use. PN 10868015, rev D, Siemens, Tarrytown (NY),
2017 Oct.
Clinical and Laboratory Standards Institute, Evaluation of Detection Capability for
Clinical Laboratory Measurement Procedures; Approved Guideline, second ed.,
Clinical and Laboratory Standards Institute, Wayne, PA, 2012 CLSI document
EP17-A2.
Clinical and Laboratory Standards Institute, Evaluation of Precision of Quantitative
Measurement Procedures; Approved Guideline, third ed., Clinical and Laboratory
Standards Institute, Wayne, PA, 2014 CLSI Document EP05-A3.
Clinical and Laboratory Standards Institute, Measurement Procedure Comparison
and Bias Estimation Using Patient Samples; Approved guideline, third ed., Clinical
and Laboratory Standards Institute, Wayne, PA, 2013 CLSI Document EP09-A3.
Clinical and Laboratory Standards Institute, Interference Testing in Clinical
Chemistry; Approved Guideline, second ed., Clinical and Laboratory Standards
Institute, Wayne, PA, 2005 CLSI document EP07-A2.
Clinical and Laboratory Standards Institute, User Protocol for Evaluation of
Qualitative Test Performance; Approved Guideline, second ed., Clinical and
Laboratory Standards Institute, Wayne, PA, 2008 CLSI document EP12-A2.
A.H.B. Wu, F. Apple, S.A. Love, D. Koch, G.L. Myers, R.H. Christenson, Creation of a
universal sample bank for determining the 99th percentile for cardiac troponin
assays, J Appl Lab Med 1 (2017) 711–719.
A. Levin, P.E. Stevens, Co-chairs:. Kidney Disease: Improving Global Outcomes
Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and
Management of Chronic Kidney Disease, Kidney Int. Suppl. 3 (2013) v-150 https://
doi.org/doi:10.1038/kisup.2012.74.
E.B. Wilson, Probable inference, the law of succession, and statistical inference, J.
Am. Stat. Assoc. 22 (1927) 209–212 https://doi.org/10.1080/01621459.1927.
10502953. JSTOR 2276774.
A.S. Go, D. Mozaﬀarian, V.L. Roger, E.J. Benjamin, J.D. Berry, M.J. Blaha, et al.,
Heart disease and stroke statistics–2014 update: a report from the American Heart

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

7

Association, Circulation 129 (2014) e28–e292 https://doi.org/10.1161/01.cir.
0000441139.02102.80.
C.A. Tomaszewski, D. Nestler, K.H. Shah, A. Sudhir, M.D. Brown, Clinical Policy:
Critical issues in the evaluation and management of emergency department patients
with suspected Non-ST-elevation acute coronary syndromes, Ann. Emerg. Med. 72
(2018) e65–e106 https://doi.org/10.1016/j.annemergmed.2018.07.045.
J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Caliﬀ, D.E. Casey
Jr.et al., ACCF/AHA focused update incorporated into the ACCF/AHA 2007
guidelines for the management of patients with unstable angina/non-ST-elevation
myocardial infarction: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol.
61 (2012) e179–347 2013 https://doi.org/10.1016/j.jacc.2013.01.014.
J.L. Forberg, L.S. Henriksen, L. Edenbrandt, U. Ekelund, Direct hospital costs of
chest pain patients attending the emergency department: a retrospective study,
BMC Emerg. Med. 6 (2006) 6 https://doi.org/10.1186/1471-227x-6-6.
C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, et al., ESC
Guidelines for the management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation: The Task Force for the management of
acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), Eur. Heart J. 32 (2011)
2999–3054 https://doi.org/10.1093/eurheartj/ehr236.
M. Roﬃ, C. Patrono, J.P. Collet, C. Mueller, M. Valgimigli, F. Andreotti, et al., ESC
Guidelines for the management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation: Task Force for the Management of Acute
Coronary Syndromes in Patients Presenting without Persistent ST-Segment
Elevation of the European Society of Cardiology (ESC), Eur. Heart J. 37 (2015)
267–315 2016 https://doi.org/10.1093/eurheartj/ehv320.
M.P. Than, J.W. Pickering, J.M. Dryden, S.J. Lord, S.A. Aitken, S.J. Aldous, et al.,
ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary
Syndrome): a study of cross-system implementation of a national clinical pathway,
Circulation 137 (2018) 354–363 https://doi.org/10.1161/circulationaha.117.
031984.
Y. Sandoval, S.W. Smith, S.A. Love, A. Sexter, K. Schulz, F.S. Apple, Single highsensitivity cardiac troponin I to rule out acute myocardial infarction, Am. J. Med.
130 (2017) 1076–1083 e1 https://doi.org/10.1016/j.amjmed.2017.02.032.
F.S. Apple, Y. Sandoval, A.S. Jaﬀe, J. Ordonez-Llanos, Cardiac troponin assays:
Guide to understanding analytical characteristics and their impact on clinical care,
Clin. Chem. 63 (2017) 73–81 https://doi.org/10.1373/clinchem.2016.255109.
I. Gunsolus, Y. Sandoval, S.W. Smith, A. Sexter, K. Schulz, C.A. Herzog, et al., Renal
dysfunction inﬂuences the diagnostic and prognostic performance of high-sensitivity cardiac troponin I, J. Am. Soc. Nephrol. 29 (2018) 636–643 https://doi.org/
10.1681/asn.2017030341.
A.R. Chapman, K.K. Lee, D.A. McAllister, L. Cullen, J.H. Greenslade, W. Parsonage,
et al., Association of high-sensitivity cardiac troponin I concentration with cardiac
outcomes in patients with suspected acute coronary syndrome, J. Am. Med. Assoc.
318 (2017) 1913–1924 https://doi.org/10.1001/jama.2017.17488.
R.H. Christenson, K. Mullins, S.H. Duh, Validation of high-sensitivity performance
for a United States Food and Drug Administration cleared cardiac troponin I assay,
Clin. Biochem. 56 (2018) 4–10 https://doi.org/10.1016/j.clinbiochem.2018.05.
004.
J. McCord, L.K. Newby, C.R. deFilippi, Designing a better mousetrap: reﬂections on
the November 28, 2017, US food and drug administration meeting on next-generation "High-Sensitivity" cardiac troponin assays to diagnose myocardial infarction, Circulation 138 (2018) 316–318 https://doi.org/10.1161/circulationaha.118.
033955.
R.M. Nowak, C.M. Gandolfo, G. Jacobsen, R.H. Christenson, M. Moyer, M. Hudson,
et al., Ultrarapid rule-out for acute myocardial infarction using the generation 5
cardiac troponin T assay: results from the REACTION-US study, Ann. Emerg. Med.
72 (2018) 654–664 https://doi.org/10.1016/j.annemergmed.2018.06.021.
R.M. Nowak, C.M. Gandolfo, G. Jacobsen, R.H. Christenson, M. Moyer, M. Hudson,
et al., 1-h evaluation for acute myocardial infarction using the generation 5 cardiac
troponin T assay, J. Am. Coll. Cardiol. 72 (2018) 2677–2679 https://doi.org/10.
1016/j.jacc.2018.08.2190.
W.F. Peacock, B.M. Baumann, D. Bruton, T.E. Davis, B. Handy, C.W. Jones, et al.,
Eﬃcacy of high-sensitivity troponin T in identifying very-low-risk patients with
possible acute coronary syndrome, JAMA cardiology 3 (2018) 104–111 https://doi.
org/10.1001/jamacardio.2017.4625.
A.S.V. Shah, Y. Sandoval, A. Noaman, A. Sexter, A. Vaswani, S.W. Smith, et al.,
Patient selection for high sensitivity cardiac troponin testing and diagnosis of
myocardial infarction: prospective cohort study, BMJ 359 (2017) j4788 https://doi.
org/10.1136/bmj.j4788.
Y. Sandoval, S.W. Smith, S.E. Thordsen, C.A. Bruen, M.D. Carlson, K.W. Dodd, et al.,
Diagnostic performance of high sensitivity compared with contemporary cardiac
troponin I for the diagnosis of acute myocardial infarction, Clin. Chem. 63 (2017)
1594–1604 https://doi.org/10.1373/clinchem.2017.272930.
F. Ford, A.S.V. Shah, R. Zhang, D.A. McAllister, F.E. Strachan, M. Caslake, et al.,
High-Sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease,
J. Am. Coll. Cardiol. 68 (2016) 2719–2728 https://doi.org/https://doi.org/10.
1016/j.jacc.2016.10.020.

